Williams, Kirsten M. and Inamoto, Yoshihiro and Im, Annie and Hamilton, Betty and Koreth, John and Arora, Mukta and Pusic, Iskra and Mays, Jacqueline W. and Carpenter, Paul A. and Luznik, Leo and Reddy, Pavan and Ritz, Jerome and Greinix, Hildegard and Paczesny, Sophie and Blazar, Bruce R. and Pidala, Joseph and Cutler, Corey and Wolff, Daniel and Schultz, Kirk R. and Pavletic, Steven Z. and Lee, Stephanie J. and Martin, Paul J. and Socie, Gerard and Sarantopoulos, Stefanie (2021) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. TRANSPLANTATION AND CELLULAR THERAPY, 27 (6). pp. 452-466. ISSN 2666-6375, 2666-6367
Full text not available from this repository. (Request a copy)Abstract
Preventing chronic graft-versus-host disease (GVHD) remains challenging because the unique cellular and molecular pathways that incite chronic GVHD are poorly understood. One major point of intervention for potential prevention of chronic GVHD occurs at the time of transplantation when acute donor anti-recipient immune responses first set the events in motion that result in chronic GVHD. After transplantation, additional insults causing tissue injury can incite aberrant immune responses and loss of tolerance, further contributing to chronic GVHD. Points of intervention are actively being identified so that chronic GVHD initiation pathways can be targeted without affecting immune function. The major objective in the field is to continue basic studies and to translate what is learned about etiopathology to develop targeted prevention strategies that decrease the risk of morbid chronic GVHD without increasing the risks of cancer relapse or infection. Development of strategies to predict the risk of developing debilitating or deadly chronic GVHD is a high research priority. This working group recommends further interrogation into the mechanisms underpinning chronic GVHD development, and we highlight considerations for future trial design in prevention trials. (C) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STEM-CELL TRANSPLANTATION; REGULATORY T-CELLS; BONE-MARROW-TRANSPLANTATION; ANTI-THYMOCYTE GLOBULIN; BRONCHIOLITIS OBLITERANS SYNDROME; KERATINOCYTE GROWTH-FACTOR; MURINE CHRONIC GVHD; B-CELLS; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; UNRELATED DONORS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 04 Oct 2022 06:16 |
| Last Modified: | 04 Oct 2022 06:16 |
| URI: | https://pred.uni-regensburg.de/id/eprint/48172 |
Actions (login required)
 |
View Item |
